AstraZeneca licenses Dizal’s lung cancer drug Zegfrovy in deal worth up to $1.5 billion
AZN•AstraZeneca gains global rights to Zegfrovy
AstraZeneca agreed to an exclusive global license with Dizal for lung cancer drug Zegfrovy (sunvozertinib), gaining worldwide development and commercialization rights.
- Deal terms include an upfront payment of USD 600 million, up to USD 900 million in development, regulatory, and sales milestones, and tiered royalties.
- Zegfrovy is marketed in the US and China for EGFR exon 20 insertion NSCLC following progression on platinum-based chemotherapy.
- The transaction is expected to close in H2 2026, subject to customary conditions and regulatory clearances.
- AstraZeneca’s 2026 financial guidance remains unchanged.
